^
over2years
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. (PubMed, ESMO Open)
Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination.
P1 data • Clinical Trial,Phase I • Journal
|
MUC1 (Mucin 1)
|
EGFR positive
|
PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
almost3years
Clinical • P2 data • Journal
|
MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
TA-MUC1 positive
|
PankoMab-GEX (gatipotuzumab)
over3years
[VIRTUAL] Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors. (ASCO 2021)
Combination of TA-MUC1 and EGFR targeting antibody is safe and feasible . Interesting anti-tumor activity was observed in heavily pretreated CRC and NSCLC patients . Levels of soluble TA-MUC1 may have predictive value and potentially be a companion biomarker for further development of the combination
Clinical • P1 data
|
MUC1 (Mucin 1)
|
Vectibix (panitumumab) • PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
over3years
Clinical • P1 data
|
MUC1 (Mucin 1)
|
Vectibix (panitumumab) • PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
4years
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
P2, N=216, Completed, Glycotope GmbH | Active, not recruiting --> Completed
Clinical • Trial completion
|
MUC16 (Mucin 16, Cell Surface Associated)
|
PankoMab-GEX (gatipotuzumab)
over4years
Clinical • P1 data • Journal • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)